Article

Natural inhibitors of DYRK1A as drug candidates against Alzheimer Disease: QSAR, molecular docking, molecular dynamics simulation and drug evaluation assessment

2023-01-09

Abstract excerpt

Alzheimer’s disease (AD) is a dementia neurodegenerative disorder with complex mechanisms and no cure that gradually leads to loss of learning, remembering, imagining, and recalling past events. It is most commonly found in adults aged 65 and up. The research scientists are interested in producing new drugs and new drug targets that can cure or inhibit this incurable disease. The In-silico technique was used to in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 70d194a1-b9e9-5a1e-addc-bd82e2d8786b
DOI: 10.21203/rs.3.rs-2443598/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Natural inhibitors of DYRK1A as drug candidates against Alzheimer Disease: QSAR, molecular docking, molecular dynamics simulation and drug evaluation assessmentDOI 10.21203/rs.3.rs-2443598/v1Read

Molecular docking studies and molecular dynamic simulation analysis: To identify novel ATP-competitive inhibition of Glycogen synthase kinase-3β for Alzheimer’s diseaseSemantic proximity Read

Identification of potential neuroprotective compound from Ganoderma lucidum extract targeting microtubule affinity regulation kinase 4 involved in Alzheimer's disease through molecular dynamics simulation and MMGBSASemantic proximity Read

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formationSemantic proximity Read

High-Throughput Screening and Molecular Dynamics Simulation of Natural Product-like Compounds against Alzheimer’s Disease through Multitarget ApproachSemantic proximity Read

Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassaySemantic proximity Read

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug DevelopmentSemantic proximity Read

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's DiseaseSemantic proximity Read

Identifying RAGE inhibitors as potential therapeutics for Alzheimer’s disease via integrated in-silico approachesSemantic proximity Read

African Natural Products for Multitarget-Based Treatment of Alzheimer’s Disease: An In Silico StudySemantic proximity Read

Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.Semantic proximity Read

Identification of Novel Chemical Entities for Mirk/Dyrk1B Receptor Using Molecular Modeling and Molecular Dynamic ApproachesSemantic proximity Read

Identification of dual inhibitors against BACE1 and GSK-3β for the treatment of Alzheimer’s disease: An in silico-based approachSemantic proximity Read